<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03024255</url>
  </required_header>
  <id_info>
    <org_study_id>BBI-4000-CL-203</org_study_id>
    <nct_id>NCT03024255</nct_id>
  </id_info>
  <brief_title>A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of 3 Concentrations of Topically Applied BBI-4000 (Sofpironium Bromide) Gel in Subjects With Axillary Hyperhidrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brickell Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brickell Biotech, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to assess the safety and efficacy of 3 concentrations of&#xD;
      BBI-4000 and vehicle (4 treatment arms), applied for the treatment of axillary hyperhidrosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Multicenter, Randomized, Double Blind, Vehicle-Controlled Study to Evaluate the&#xD;
      Safety and Efficacy of 3 concentrations of Topically Applied BBI-4000 in Subjects with&#xD;
      Axillary Hyperhidrosis.&#xD;
&#xD;
      Safety will be assessed through collection of vital signs, adverse events, local skin&#xD;
      responses, hematology, serum chemistry laboratory testing and urinalysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hyperhydrosis severity questionnaire</measure>
    <time_frame>6 Weeks</time_frame>
    <description>An 11 question evaluation tool to assess the effect of BBI-4000 5%, 10% and 15 % gel on hyperhidrosis disease severity measure when applied topically in subjects with axillary hyperhidrosis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events, local tolerability assessments, vital signs and laboratory tests</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Evaluation of the safety and local tolerability of 3 concentrations of BBI-4000 gel when applied topically in subjects with axillary hyperhidrosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gravimetric sweat production</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Measured weight of the amount of sweat produced</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">227</enrollment>
  <condition>Hyperhidrosis</condition>
  <arm_group>
    <arm_group_label>BBI-4000 Concentration 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Concentration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BBI-4000 Concentration 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium Concentration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BBI-4000 Concentration 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Concentration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle (Placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBI-4000 Concentration 1</intervention_name>
    <description>Lowest test dose</description>
    <arm_group_label>BBI-4000 Concentration 1</arm_group_label>
    <other_name>BBI-4000 Low Concentration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBI-4000 Concentration 2</intervention_name>
    <description>Test dose between high and low concentrations</description>
    <arm_group_label>BBI-4000 Concentration 2</arm_group_label>
    <other_name>BBI-4000 Medium Concentration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBI-4000 Concentration 3</intervention_name>
    <description>Highest test dose</description>
    <arm_group_label>BBI-4000 Concentration 3</arm_group_label>
    <other_name>BBI-4000 High Concentration</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle (Placebo)</intervention_name>
    <description>Vehicle without drug</description>
    <arm_group_label>Vehicle</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subject ≥ 18 years of age.&#xD;
&#xD;
          -  Diagnosis of primary axillary hyperhidrosis that meets the following criteria: (a)&#xD;
             symptoms of hyperhydrosis for at least 6 months' duration, (b) HDSM-Ax of 3 - 4, (c)&#xD;
             HDSS of 3 or 4 and (d) a minimum GSP of 50 mg is each axilla with a combined total of&#xD;
             at least 150 mg.&#xD;
&#xD;
          -  The ability to understand and follow all study-related procedures including study drug&#xD;
             administration.&#xD;
&#xD;
          -  Sexually active female of childbearing potential (FOCBP)* must agree to periodic&#xD;
             pregnancy testing and use a medically acceptable method of contraception while&#xD;
             receiving protocol-assigned product.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  In the Investigators opinion, any skin or subcutaneous tissue conditions of the&#xD;
             axilla(s).&#xD;
&#xD;
          -  Prior use of any prohibited medication(s) or procedure(s) within the specified&#xD;
             timeframe for the treatment of axillary hyperhidrosis.&#xD;
&#xD;
          -  Anticholinergic agents used to treat conditions such as, but not limited to,&#xD;
             hyperhidrosis, asthma, incontinence, gastrointestinal cramps, and muscular spasms by&#xD;
             any route of administration.&#xD;
&#xD;
          -  Use of potent inhibitors of cytochrome P450 CYP3A and CYP2D6.&#xD;
&#xD;
          -  Use of any cholinergic drug (e.g. bethanechol) within 30 days.&#xD;
&#xD;
          -  Known cause of hyperhidrosis or known history of a condition that may cause&#xD;
             hyperhidrosis (i.e., hyperhidrosis secondary to any known cause such hyperthyroidism,&#xD;
             diabetes mellitus, medications, etc.).&#xD;
&#xD;
          -  Subjects with unstable diabetes mellitus or thyroid disease, history of renal or&#xD;
             hepatic impairment, malignancy glaucoma, intestinal obstructive or motility disease,&#xD;
             obstructive uropathy, myasthenia gravis, BPH, neurological or psychiatric conditions,&#xD;
             Sjögren's or Sicca syndrome, or cardiac abnormalities that may alter or exacerbate&#xD;
             sweat production by the use of anticholinergics in the investigator's opinion.&#xD;
&#xD;
          -  Subjects with known hypersensitivity to glycopyrrolate, anticholinergics, or any of&#xD;
             the components of the topical formulation.&#xD;
&#xD;
          -  Subject is pregnant, lactating or is planning to become pregnant during the study.&#xD;
&#xD;
          -  History or presence of supraventricular tachycardia, ventricular arrhythmias, atrial&#xD;
             fibrillation or atrial flutter.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence A Romel, MS</last_name>
    <role>Study Director</role>
    <affiliation>Brickell Biotech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IHHS Call Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29492</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>January 6, 2017</study_first_submitted>
  <study_first_submitted_qc>January 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2017</study_first_posted>
  <disposition_first_submitted>July 17, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>July 18, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 20, 2018</disposition_first_posted>
  <last_update_submitted>July 18, 2018</last_update_submitted>
  <last_update_submitted_qc>July 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sweat gland disease</keyword>
  <keyword>sweating</keyword>
  <keyword>underarm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperhidrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

